The Cigna Group is expected to report Q2 2026 revenue of $64.42 billion and EPS of $7.58, with the current stock price of $382.45 trading below the average analyst price target of $438.20. Investors are primarily focused on the Medical Care Ratio (MCR) to determine how Cigna is managing healthcare utilization trends relative to its managed care peers.
Strength in the Evernorth health services segment remains a critical driver, particularly the impact of rising GLP-1 drug demand on specialty pharmacy volumes and margins. Management's updated 2026 guidance will be essential to confirm if the company can maintain its double-digit earnings growth trajectory despite ongoing regulatory shifts in the pharmacy benefit management sector.